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© 2010 The Japan Society of Histochemistry and Cy- The clinical study for lingual disease requires the detailed investigation of the lingual lym-
phatic network and lymphatic marker-positive cells. Recently, it has been reported that sev-
eral tissue cells and leukocytes express lymphatic markers, LYVE-1 and podoplanin. This
study was aimed to clarify the lingual distribution of cells expressing LYVE-1 and podoplanin.
In the mouse tongue, podoplanin is expressed in nerve sheaths, lingual gland myoepithelial
cells, and lymphatic vessels. LYVE-1 is expressed in the macrophage marker Mac-1-positive
cells as well as lymphatic vessels, while factor-VIII was detected in only blood endothelial
cells. α-SMA was detected in vascular smooth muscle and myoepithelial cells. Therefore,
identification of lymphatic vessels in lingual glands, the combination of LYVE-1 and factor-
VIII, or LYVE-1 and Mac-1 is useful because myoepithelial cells express podoplanin and α-
SMA. The immunostaining of factor-VIII on lymphatic vessels was masked by the immuno-
staining to LYVE-1 or podoplanin because lymphatic vessels express factor-VIII to a far
lesser extent than blood vessels. Therefore, except for the salivary glands, the combination
of podoplanin and α-SMA, or factor-VIII is useful to identify lymphatic vessels and blood
vessels with smooth muscle, or blood capillaries.
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I. Introduction
The recent discovery of lymphatic endothelial cell
markers, such as PROX1 [37], lymphatic vessel endothelial
hyaluronan receptor 1 (LYVE-1) [1], and podoplanin, made
lymphology progress greatly at the molecular biology level
[2]. Homeobox gene PROX1 induces the lymphatic devel-
opment independent of the vascular system development
from embryonic veins, and homozygous PROX1-null mouse
embryos die at birth because of multiple developmental
defects. PROX1 is a master regulator of podoplanin expres-
sion and enables vascular endothelial cells to reprogram to
become lymphatic endothelial cells. However, PROX-1 is
difficult to use for the clinical identification of lymphatic
vessels because of the transient expression in a nucleus
[6, 11, 25, 37]. Podoplanin is a mucin-type 38-kDa trans-
membrane glycoprotein negatively charged by extensive O-
glycosylation and has a high content of sialic acid [8,
16, 18, 29, 31, 33]. Podoplanin was first identified as the
antigen of kidney glomerular epithelial cells, the podocytes
[2], and is also homologous to T1α-2 gene which encodes
the type I alveolar cell specific antigen and to the oncofetal
antigen M2A recognized by the D2-40 antibody [4, 17,
20, 26–28, 38]. Podoplanin is first expressed at around E11.0
in Prox1-positive lymphatic progenitor cells. Podoplanin
(−/−) mice die at birth because of the respiratory failure
and have defects in lymphatic formation with diminished
lymphatic transport and congenital lymphedema, but do not
have defects in blood vessel pattern formation [30]. We
have recently reported that the lymphatic endothelium
significantly increases podoplanin expression by the recog-
nition of lipopolysaccharide and lipoteichoic acid through
Toll-like receptors 2 and 4 [19]. In other somatic tissue
cells, the expression of podoplanin is found in myoepithelialNoda et al. 62
cells of salivary glands [9]. The podoplanin expression is
rarely found in acini of the parotid gland but clearly found
at the basal portion of acini in the submandibular and sub-
lingual glands. Strong expression of podoplanin is also
found at the basal portion of the intercalated duct, striated
duct, and interlobular duct in all major salivary glands.
Podoplanin could be a marker protein of salivary gland
myoepithelial cells because podoplanin detection levels
coincide with the distribution of myoepithelial cells specific
for major salivary glands. In the tooth germ, podoplanin
is strongly expressed in inner and outer enamel epithelia at
the early bell stage. The strong expression of podoplanin
in odontoblasts is sustained during the dentin formative
period and diminished at the root formation stage [29].
Recently, it was shown that lymphatic vessels have the
ability to express diverse leukocyte adhesion molecules in
inflamed lingual tissue [13]. Clinical study for the infectious
disease of the tongue requires detailed investigation of the
lymphatic vessel network of the apex linguae to the submen-
tal lymph nodes and of the radix linguae to jugular vein
digastric muscle lymph nodes, and on the initial lymphatic
distribution in the tunica muscularis and lamina propria
mucosae of the tongue. On the other hand, there have been
reports for the expression of the lymphatic marker podopla-
nin in somatic cells including dendritic cells [20, 39], osteo-
blasts [8, 35], and epidermal cells [21–23, 26, 28], as well as
salivary gland myoepithelial cells [9]. Therefore, in order to
precisely identify the lingual lymphatic vessels, it is neces-
sary to investigate the distribution of cells expressing lym-
phatic markers except for podoplanin. However, there has
been no report that has investigated the correlation between
podoplanin-positive cells and cells expressing other lym-
phatic markers like LYVE-1. LYVE-1 is selectively ex-
pressed in lymphatic endothelial cells [1, 14] in a subset of
infiltrating macrophages found in tumors and inflamed
tissues [3], and in the sinusoidal endothelium of liver and
spleen. LYVE-1 knockout mice display an apparently nor-
mal phenotype with no visible alterations in hyaluronan
metabolism, lymphatic vessel development and mainte-
nance, or macrophage trafficking [5, 12]. LYVE-1 is also
upregulated in macrophages by a variety of growth factors
and cytokines in inflammatory conditions [32]. Therefore,
the utility of lymphatic endothelial antigens may vary
between tissues. This study aimed to investigate the corre-
lation among cells expressing podoplanin and LYVE-1 as
the lymphatic vessel markers, factor-VIII related antigen
(factor-VIII) and α-smooth muscle actin (α-SMA) as the
blood vessel markers, and Mac-1 as a macrophage marker.
II. Materials and Methods
Immunohistochemistry
The lingual tissue of 8-week-old closed colony ICR
mice (male, n=5; Charles River Japan Inc., Yokohama,
Japan) was used. Tissue was obtained after euthanasia
by intraperitoneal injection with sodium pentobarbital
(10 ml/kg, Nembutal, Abbott Laboratories, North Chicago,
IL, USA). The protocol for animal use was reviewed and
approved by the animal experiment committee of Fukuoka
Dental College, Fukuoka, Japan. Frozen 8 μm sections
were cut in a cryostat and fixed in 100% methanol for 2
min at −20°C. After treatment with 0.1% goat serum, the
sections were treated with a cocktail of first antibodies:
0.5 μg/ml of hamster anti-mouse podoplanin (monoclonal;
AngioBio Co., Del Mar, CA, USA), rabbit anti-α-smooth
muscle actin (monoclonal; Epitomics, Inc., Burlingame,
CA, USA), rat anti-mouse CD11b/Mac-1 a chain (mono-
clonal; BD Biosciences, San Jose, CA, USA), rabbit anti-
factor-VIII (polyclonal; Biogenesis Ltd., Poole, UK), and
rat anti-mouse LYVE-1 (monoclonal; R&D systems Inc.,
Minneapolis, MN, USA) for 8 hr at 4°C. After reacting
with first antibodies, the sections were immunostained
for 0.5 hr at 20°C with a cocktail of second antibodies (0.1
μg/ml): AlexaFluor (AF) 488 or 568-conjugated goat anti-
hamster, rabbit or rat IgGs (Molecular Probes, Invitrogen
Com., Eugene, OR, USA), and examined by fluorescence
microscopy BZ-8100 (Keyence Corp., Osaka, Japan) [7, 10,
13, 24, 32].
III. Results
In the double immunostaining for podoplanin and
LYVE-1 of the tunica musclaris of the mouse apex linguae,
there were nerve sheaths stained with only anti-podoplanin
antibody, single cells with only anti-LYVE-1 antibody, and
lymphatic vessels with both anti-podoplanin and anti-
LYVE-1 antibodies (Fig. 1). In the double immunostaining
for LYVE-1 and Mac-1 of the lamina propria mucosae of the
mouse apex linguae, there were lymphatic vessels stained
with only anti-LYVE-1 antibody, macrophages with only
anti-Mac-1 antibody, and macrophages with both anti-
LYVE-1 and anti-Mac-1 antibodies (Fig. 2). In the double
immunostaining for podoplanin and α-SMA of the lamina
propria mucosae of the mouse radix linguae, lymphatic
vessels and blood vessels were stained with only anti-
podoplanin antibody and anti-α-SMA antibody, respective-
ly (Fig. 3). It was also observed that in the lingual gland,
which is a mixed minor salivary gland composed of mu-
cous and serous acini, the myoepithelial cells surrounding
acinar cells were all stained with both anti-podoplanin and
anti-α-SMA antibodies (Fig. 3). In the double immunostain-
ing for LYVE-1 and factor-VIII of the mouse sublingual
gland which is a mixed major salivary gland mainly com-
posed of mucous acini, lymphatic vessels and blood vessels
were stained with only anti-LYVE-1 antibody and anti-
factor-VIII antibody, respectively, and there were no myo-
epithelial, duct and acinar cells, expressing LYVE-1 or
factor-VIII (Fig. 4). In the double immunostaining for podo-
planin and α-SMA of the tunica muscularis of the mouse
radix linguae, lymphatic vessels and blood vessels were
stained  with  only  anti-podoplanin  antibody  and  anti-α-
SMA antibody, respectively, and there were nerve sheaths
stained with only anti-podoplanin antibody (Fig. 5). In the
double immunostaining for LYVE-1 and factor-VIII ofPodoplanin and LYVE-1 in Oral Tissue 63
Fig. 1. Immunostaining for podoplanin and LYVE-1 of mouse apex linguae sections. H-E staining shows the intrinsic lingual muscle and nerve
sheaths in the tunica muscularis. Nerve sheaths are stained with only anti-podoplanin antibody in green (arrows), single cells with only anti-
LYVE-1 antibody in red (arrowheads), and lymphatic vessels with both anti-podoplanin and anti-LYVE-1 antibodies in yellow (asterisk).
Bar=100 μm.
Fig. 2. Immunostaining for LYVE-1 and Mac-1 of mouse apex linguae sections. The H-E staining shows the lamina propria mucosae and the
intrinsic lingual muscle in the lamina propria mucosae. Lymphatic vessels stained with only anti-LYVE-1 antibody in green (arrows), macro-
phages with only anti-Mac-1 antibody in red (asterisks), and macrophages with both anti-LYVE-1 and anti-Mac-1 antibodies in yellow
(arrowheads). Bar=100 μm.Noda et al. 64
Fig. 3. Immunostaining for podoplanin and α-SMA of mouse radix linguae sections. H-E staining shows that the lingual gland is a mixed minor
gland composed of mucous acini (arrows) and serous acini (arrowheads) in the radix linguae. In the lamina propria mucosae lymphatic vessels
are stained with only anti-podoplanin antibody in green (yellow arrowheads) and blood vessels with only anti-SMA antibody in red (white
arrowhead). In the lingual gland myoepithelial cells, the surrounding acinar cells are all stained with both anti-podoplanin and anti-α-SMA
antibodies. Bar=100 μm.
Fig. 4. Immunostaining for LYVE-1 and factor-VIII of the mouse sublingual gland. H-E staining shows that the intercalated ducts, having a
narrow lumen surrounded by cuboidal cells, are interposed between acinar cells, and that the striated ducts (asterisks) are composed of columnar
cells with acidophilic cytoplasm. Lymphatic vessels are stained with only anti-LYVE-1 antibody in green (arrows) and the blood vessels with
only anti-factor-VIII antibody in red (arrowheads). Duct and acinar cells are stained by neither anti-LYVE-1 nor anti-factor-VIII antibodies.
There are few LYVE-1-positive macrophages compared with tongue tissue. Bar=100 μm.Podoplanin and LYVE-1 in Oral Tissue 65
Fig. 5. Immunostaining for podoplanin and α-SMA of mouse radix linguae sections. The H-E staining shows the intrinsic lingual muscle and
nerve sheaths in the tunica muscularis. Nerve sheaths (arrows) and lymphatic vessels (arrowheads) are stained with only anti-podoplanin
antibody in green, and blood vessels with vascular smooth muscle cells are stained by anti-SMA antibody in red (asterisks). Bar=100 μm.
Fig. 6. Immunostaining for LYVE-1 and factor-VIII of mouse apex linguae sections. The H-E staining shows the lamina propria mucosae
and the intrinsic lingual muscle in the tunica muscularis. In the lamina propria mucosae, lymphatic vessels (arrow) and single cells, which could
be identified as macrophages with the unstained nucleus (asterisks), are all stained with only anti-LYVE-1 antibody in green, and the blood
capillaries are stained with only anti-factor-VIII antibody in red (arrowheads). Bar=100 μm.Noda et al. 66
the lamina propria mucosae of the mouse apex linguae,
lymphatic vessels and blood vessels were stained with only
anti-podoplanin antibody and factor-VIII antibody, respec-
tively (Fig. 6).
IV. Discussion
In the comparison of podoplanin-positive and LYVE-
1-positive cells in the tunica musclaris and lamina propria
mucosae of mouse apex linguae, it was shown that podo-
planin is expressed in nerve sheaths as well as lymphatic
vessels, and that LYVE-1 is expressed in macrophages as
well as lymphatic vessels (Figs. 1, 2). There is no report
on the podoplanin expression in nerve-associated cells
under normal conditions except for schwanoma [15]. The
LYVE-1 and CD44 are the two most abundant receptors
for the extracellular matrix glycosaminoglycan hyaluronan
while LYVE-1 is the lymph-specific hyaluronan receptor
on the luminal side of the lymphatic vessel wall [1, 5, 14].
CD44 and LYVE-1 bind both soluble and immobilized
hyaluronan; however, unlike CD44, LYVE-1 is completely
absent from blood vessels. LYVE-1 is a type I integral
membrane protein and consists of a 322-residue polypep-
tide of which the sequence is 41% similar to CD44 having
a 212-residue extracellular domain containing a prototypic
hyaluronan-binding region. A copolymer of GlcNAc and
GlcUA, glycosaminoglycan hyaluronan, is an abundant com-
ponent of extracellular matrix and facilitates cell migration
in inflamed mesenchymal tissues. Most of the hyaluronan
in the tissue are turned over, collected in lymphatic vessels,
and degraded in the medullary sinuses of lymph nodes [1,
5, 12, 14]. Recently, it has been reported that LYVE-1 is
expressed by Mac-1-positive macrophages in malignant
tumor and wound healing tissues. The CD44 is expressed
on leukocytes and contributes to the traffic through tissues,
while LYVE-1 regulates not only hyaluronan transporta-
tion but also macrophage migration by the binding func-
tion between LYVE-1 and hyaluronan [3, 14, 32]. The lym-
phatic vessels may play a role to control edema through
hyaluronan transportation by LYVE-1. Podoplanin may be
more useful than LYVE-1 to identify initial lymphatics in
the oral mucosa tissue because of the difficulties of dis-
criminating initial lymphatic endothelial cells from macro-
phages without Mac-1.
In the comparison of podoplanin-positive and α-SMA-
positive cells in the lamina propria mucosae of the mouse
radix linguae, it was shown that podoplanin and α-SMA
are expressed in lymphatic vessels and in blood vessels,
respectively. It was also observed that both podoplanin
and α-SMA are expressed in the lingual gland (Fig. 3). In
an earlier study, we initially investigated the distribution
of lymphatic vessels in major salivary grands by immuno-
staining for the lymphatic endothelial cell marker, podo-
planin, and discovered that most podoplanin-positive cells
in major salivary glands were myoepithelial cells rather than
lymphatic endothelial cells by immunostaining for podo-
planin and myoepithelial cell marker P-cadherin [9]. In
the present study on the minor salivary gland of the tongue
it was shown that podoplanin-positive cells are myoepithe-
lial cells because the podoplanin-positive region accorded
with the α-SMA-positive region in lingual glands. In the
mouse sublingual gland, it was shown that LYVE-1 and
factor-VIII are expressed in lymphatic vessels and in blood
vessels, respectively, and that there were no myoepithelial
cells expressing LYVE-1 or factor-VIII (Fig. 4). There were
also LYVE-1-positive macrophages at a lesser extent than
in the lingual tissue. On the identification of the lymphatic
vascular distribution in both minor and major salivary
glands, it is thought that the combination of LYVE-1 and
factor-VIII, or LYVE-1 and Mac-1 are more useful than
podoplanin alone because myoepithelial cells also express
podoplanin.
In the tunica muscularis of mouse radix linguae, it was
shown that podoplanin and α-SMA are expressed in lym-
phatic vessels and in blood vessels, respectively (Fig. 5). It
is thought that the combination of podoplanin and α-SMA is
useful to distinguish between lymphatic vessels and blood
vessels having vascular smooth muscle cells in the oral tis-
sues except for salivary glands [7, 34]. In Figures 1 and 5,
the podoplanin-positive organ was identified as nerve
sheaths based on haematoxylin-eosin (H-E) findings and on
the expression of neither LYVE-1 nor α-SMA in the tunica
musclaris of both apex and radix linguae. The general ex-
pression of podoplanin in nerve sheaths should be investi-
gated. Recently, podoplanin upregulation has been reported
in oral squamous cell carcinomas [26, 36]. Sixty percent of
oral tongue cancers express high levels of podoplanin. Pa-
tients with high levels of podoplanin have a statistically sig-
nificantly higher rate of lymph node metastasis and those
with lymph node metastasis high-levels of podoplanin show
the shortest disease-specific survival than other patients.
These reports suggest that podoplanin serves as a predictor
for the risk for lymph node metastasis and poor clinical
outcome [17, 21, 40]. Therefore, it would be important to
investigate the podoplanin expression in oral cancer but it
is necessary to discriminate between oral cancer cells and
initial lymphatic endothelium by using other markers like
LYVE-1.
In the lamina propria mucosae of mouse apex linguae,
it was shown that LYVE-1 and factor-VIII are expressed in
lymphatic vessels and in blood vessels, respectively (Fig. 6).
Factor-VIII but not α-SMA should be targeted to identify
blood capillaries because there are no no vascular smooth
muscle cells in the capillaries. It is known that factor-VIII
exists not only in blood vessels but also lymphatic vessels,
and that the expression level is extremely lower in lymphatic
vessels than blood vessels [24]. Since the immunostaining of
factor-VIII on the lymphatic vessels was completely masked
by the strong immunostaining to LYVE-1 (Fig. 6), it seems
that factor-VIII is useful to distinguish blood capillaries
from initial lymphatics immunostained with anti-podoplanin
and anti-LYVE-1 antibodies. However, in order to identify
initial lymphatics by LYVE-1, it is necessary to distinguish
LYVE-1-positive vessels from macrophages by a markerPodoplanin and LYVE-1 in Oral Tissue 67
like Mac-1.
In conclusion for the molecules to identify the lingual
initial lymphatics, podoplanin should be chosen rather than
LYVE-1 because of LYVE-1-positive macrophages in the
normal oral mucosa whereas LYVE-1 should be chosen
rather than podoplanin because of podoplanin-positive myo-
epithelial cells and oral cancer cells in the salivary glands
and oral squamous cell carcinomas.
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